Medical Imaging
in Clinical Trials

Medical imaging is used for eligibility, safety and efficacy endpoints in clinical trials. The Bracken team builds on years of strategic and operational experience to help clients develop and design the imaging aspects of their clinical trials. 

We offer comprehensive support in biomarker selection and development, CRO/vendor selection, biopharmaceutical products, novel diagnostic imaging products, precision medicine, managing core labs and vendors, patient-focused drug development, and clinical and imaging strategy and protocol development. 

Bracken’s integrated approach to medical imaging offers support that’s not just intellectual, it’s interpersonal.

• Having worked at imaging core labs and embedded imaging teams at pharma companies, our experts have rare, in-depth knowledge of how medical imaging can be used to provide biomarkers in clinical trials and help get products to market.
• We have the domain knowledge and hands-on experience to effectively manage imaging CROs and vendors, including handling imaging rescue studies. Our team includes a trusted network of top-tier imaging, statistical, operational, and regulatory SMEs. 
• One of our founders, Dr. Colin G. Miller, is a co-author of Medical Imaging in Clinical Trials. Published by Springer, the book is the “go-to” text for anyone using medical imaging in clinical trials.
• Most recently, the Bracken team has been at the forefront of the growth of radiopharmaceuticals, both in the development of novel diagnostics and in the rapidly developing field of theranostics.

Endpoints play a pivotal role in advancing precision medicine, but their true value depends on the quality of medical image acquisitions and the expertise of radiologists interpreting them.

The experience of working at the intersection of medical imaging and clinical research has provided the Bracken consulting team with the knowledge and insight to help you:

1. Select the appropriate imaging endpoints for your trial so that you can most readily make go/no-go decisions. Optimize the protocol language for your imaging endpoints to reduce costly protocol revisions.
2. Survey the imaging literature to evaluate level of validation and potential gaps in proposed endpoints.
3. Connect you with KOLs to achieve maximum scientific credibility.
4. Ensure the imaging endpoints are robustly implemented.
5. Work with your team to develop a request for proposal and select the best CRO to implement your imaging study.
6. Certify that you are only paying for the imaging services you need for your study's integrity.
7. Manage your vendors to ensure quality delivery of the data.
8. Represent your team’s interests in delivering the study.

How? By asking the right questions:

Is Your Study In Focus? Questions to Ask for Successful Medical Imaging:

• Which imaging core lab should you select? They all have their key strengths, but which ones match your needs?
• What kind of read should we employ? 2+1? Forced or open adjudication? How many readers?
• How should we assess intra- and inter- reader variability? What should the adjudication rate be for this indication?
• Should I have a reader calibration training kick-off meeting?
• Local sites have radiologists. Why don’t we leave it up to the local experts to make the decision?
• Is a central read cost effective in my clinical trial?
• What type of reader paradigm should I use for oncology: RECIST 1.1? Lesion volume? Lugano? RANO? Other modifications?
• What type of should be used for osteoarthritis? Osteoporosis? Rheumatoid Arthritis? Inflammatory Arthritis? 
• Do I need a radiologist reading DXA studies?
• Does the Imaging Charter capture the necessary details?

Most core labs lack staff with direct experience in the pharma and biotech industries, limiting their nuanced understanding of critical decision-making.

Similarly, most pharma teams have limited expertise in medical imaging. 

Bracken is here to bridge these gaps in knowledge.

DOWNLOAD OUR IMAGING CHARTER CHECKLIST